Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 3 | US | 10 Jul 2020 | |
Solid tumor | Phase 3 | CA | 10 Jul 2020 | |
Bladder Cancer | Phase 2 | US | 22 Nov 2021 | |
Metastatic Solid Tumor | Phase 1 | CA | 10 Jul 2020 | |
Metastatic Solid Tumor | Phase 1 | US | 10 Jul 2020 | |
Metastatic Solid Tumor | Phase 1 | - | 10 Jul 2020 | |
Transitional Cell Carcinoma | Preclinical | US | 14 Apr 2022 |
NCT04457778 (AACR2024) Manual | Phase 1 | 58 | (goabppwzhk) = Overall, two dose-limiting toxicities were observed: a grade 3 adrenal insufficiency (M6223, 900 mg) and a grade 3 anemia (M6223+BA, 300 mg; unrelated to M6223). camokllrts (muqvlszmix ) View more | Positive | 05 Apr 2024 | ||
NCT04457778 (ESMO2022) Manual | Phase 1 | 41 | (jznxnsbkto) = zhbzxznarq fnpnwsgyao (eaihiijuhg ) View more | Positive | 10 Sep 2022 | ||
(jznxnsbkto) = zlrwqisjmu fnpnwsgyao (eaihiijuhg ) View more |